Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Anders

Showing results (161-170 of 271) with videos related to

Pageof 28
Sort By:
Pediatric Blood & Cancer|May 7, 2009
Initial testing (stage 1) of vorinostat (SAHA) by the pediatric preclinical testing programNino Keshelava, Peter J Houghton, Christopher L Morton, et al.
Pediatric Blood & Cancer|May 7, 2009
Initial testing of aplidin by the pediatric pre-clinical testing programChristopher L Morton, Peter J Houghton, Richard Gorlick, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 28, 2021
Gemtuzumab Ozogamicin Improves Event-Free Survival and Reduces Relapse in Pediatric <i>KMT2A</i>-Rearranged AML: Results From the Phase III Children's Oncology Group Trial AAML0531Jessica A Pollard, Erin Guest, Todd A Alonzo, et al.
Clinical and Translational Science|July 7, 2023
Comparison of variants in TPMT and NUDT15 between sequencing and genotyping methods in a multistate pediatric institutionKelsey J Cook, Victoria Grusauskas, Lucy Gloe, et al.
Pediatric Blood & Cancer|November 5, 2011
Initial testing (stage 1) by the pediatric preclinical testing program of RO4929097, a γ-secretase inhibitor targeting notch signalingE Anders Kolb, Richard Gorlick, Stephen T Keir, et al.
Pediatric Blood & Cancer|October 28, 2016
Initial testing of VS-4718, a novel inhibitor of focal adhesion kinase (FAK), against pediatric tumor models by the Pediatric Preclinical Testing ProgramRaushan T Kurmasheva, Richard Gorlick, E Anders Kolb, et al.
Pediatric Blood & Cancer|January 29, 2010
Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP)John M Maris, Christopher L Morton, Richard Gorlick, et al.
Pediatric Blood & Cancer|June 18, 2011
Initial testing (stage 1) of LCL161, a SMAC mimetic, by the Pediatric Preclinical Testing ProgramPeter J Houghton, Min H Kang, C Patrick Reynolds, et al.
Pediatric Blood & Cancer|June 27, 2013
Initial testing (Stage 1) of the antibody-maytansinoid conjugate, IMGN901 (Lorvotuzumab mertansine), by the pediatric preclinical testing programAndrew C Wood, John M Maris, Richard Gorlick, et al.
Pediatric Blood & Cancer|December 18, 2009
Initial testing of topotecan by the pediatric preclinical testing programHernan Carol, Peter J Houghton, Christopher L Morton, et al.
Pageof 28

Showing results (161-170 of 271) with videos related to

Sort By:
Pageof 28
Pediatric Blood & Cancer|May 7, 2009
Initial testing (stage 1) of vorinostat (SAHA) by the pediatric preclinical testing programNino Keshelava, Peter J Houghton, Christopher L Morton, et al.
Pediatric Blood & Cancer|May 7, 2009
Initial testing of aplidin by the pediatric pre-clinical testing programChristopher L Morton, Peter J Houghton, Richard Gorlick, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 28, 2021
Gemtuzumab Ozogamicin Improves Event-Free Survival and Reduces Relapse in Pediatric <i>KMT2A</i>-Rearranged AML: Results From the Phase III Children's Oncology Group Trial AAML0531Jessica A Pollard, Erin Guest, Todd A Alonzo, et al.
Clinical and Translational Science|July 7, 2023
Comparison of variants in TPMT and NUDT15 between sequencing and genotyping methods in a multistate pediatric institutionKelsey J Cook, Victoria Grusauskas, Lucy Gloe, et al.
Pediatric Blood & Cancer|November 5, 2011
Initial testing (stage 1) by the pediatric preclinical testing program of RO4929097, a γ-secretase inhibitor targeting notch signalingE Anders Kolb, Richard Gorlick, Stephen T Keir, et al.
Pediatric Blood & Cancer|October 28, 2016
Initial testing of VS-4718, a novel inhibitor of focal adhesion kinase (FAK), against pediatric tumor models by the Pediatric Preclinical Testing ProgramRaushan T Kurmasheva, Richard Gorlick, E Anders Kolb, et al.
Pediatric Blood & Cancer|January 29, 2010
Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP)John M Maris, Christopher L Morton, Richard Gorlick, et al.
Pediatric Blood & Cancer|June 18, 2011
Initial testing (stage 1) of LCL161, a SMAC mimetic, by the Pediatric Preclinical Testing ProgramPeter J Houghton, Min H Kang, C Patrick Reynolds, et al.
Pediatric Blood & Cancer|June 27, 2013
Initial testing (Stage 1) of the antibody-maytansinoid conjugate, IMGN901 (Lorvotuzumab mertansine), by the pediatric preclinical testing programAndrew C Wood, John M Maris, Richard Gorlick, et al.
Pediatric Blood & Cancer|December 18, 2009
Initial testing of topotecan by the pediatric preclinical testing programHernan Carol, Peter J Houghton, Christopher L Morton, et al.
Pageof 28